GW Pharma (GWPH) Shares Pressured; Abstract Confirms Interactions Between CBD and Clobazam in RE

November 21, 2016 2:10 PM EST

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

GW Pharma (NASDAQ: GWPH) shares are lower following release of an abstract ahead of the American Epilepsy Society's Annual Meeting. The abstract covers potential interactions between pharmaceutical grade CBD (Epidiolex) and AEDs by monitoring of serum AED levels during active titration of CBD in patients with treatment refractory epilepsy enrolled in an open label safety study.

The abstract concluded: Significant drug interactions were identified between CBD and clobazam, rufinamide, topiramiate, zonisamide, and eslicarbazepine. This study emphasizes the importance of monitoring AED levels during treatment with CBD. In the future, these data will need to be correlated with reported side effects and/or lab abnormalities to determine if they are clinically significant.

The AES Annual Meeting runs from December 2 - 6, 2016.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Add Your Comment